Symbol | Exchange | Currency |
---|
Guardant Health (NASDAQ:GH) reported Q2 EPS of ($1.00), $0.21 better than the analyst estimate of ($1.21). Revenue for the quarter came in at $109.1 million versus the consensus...
Leerink Partners analyst Puneet Souda maintained a Buy rating on Guardant Health (NASDAQ:GH) on Tuesday, setting a price target of $180, which is approximately 42.33% above the...
We’re in the thick of big tech earnings right now and also had to deal with a Fed statement on Wednesday, so it’s no surprise that today’s session saw an...
Exact Sciences (NASDAQ:EXAS) EXAS is the $19 billion leader in proactive cancer diagnostics with the Cologuard screening kit, which the majority of healthcare providers are...
SPECIAL ALERT: Remember, the March episode of the Zacks Ultimate Strategy Session is now available for viewing! Don’t miss your chance to hear: ▪ Jeremy Mullin and Brian...
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Strong Buy | Neutral | Sell | Sell | Sell |
Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Neutral | Strong Sell |
Summary | Strong Buy | Buy | Strong Sell | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
48.58 | 49.52 | 48.38 | -0.69 | -1.40% | 18.48M | NYSE | |||
166.77 | 168.30 | 165.93 | -0.81 | -0.48% | 8.30M | NYSE | |||
120.86 | 121.68 | 119.56 | +0.54 | +0.45% | 15.38M | NASDAQ | |||
18.55 | 20.81 | 16.16 | -4.53 | -19.63% | 136.95M | NASDAQ | |||
55.99 | 56.08 | 55.90 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
26.30 | 26.38 | 25.86 | +0.18 | +0.69% | 158.88K | NYSE | |||
75.25 | 75.28 | 74.28 | +0.51 | +0.68% | 307.16K | NASDAQ | |||
7.66 | 7.72 | 7.63 | +0.03 | +0.39% | 4.19M | NASDAQ | |||
439.35 | 444.58 | 436.87 | -2.24 | -0.51% | 851.29K | NYSE | |||
100.44 | 101.07 | 96.73 | +2.17 | +2.21% | 75.87M | NASDAQ | |||
0.97 | 0.98 | 0.92 | +0.03 | +2.67% | 42.62K | NASDAQ | |||
150.00 | 158.51 | 148.26 | -8.00 | -5.06% | 6.91M | NASDAQ | |||
51.46 | 51.93 | 48.42 | +3.62 | +7.57% | 6.15M | NYSE | |||
90.68 | 91.88 | 88.52 | +0.91 | +1.01% | 13.01M | NYSE | |||
0.65 | 0.66 | 0.61 | +0.02 | +3.05% | 6.29M | NYSE |